三苯双脒抗肠道蠕虫感染的进一步临床观察和实验研究的新进展  

Further clinical observation on tribendimidine against intestinal helminth infection and the new progress in laboratory study

作　　者：肖树华[1] 

机构地区：[1]中国疾病预防控制中心寄生虫病预防控制所卫生部寄生虫病原与媒介生物学重点实验室世界卫生组织疟疾血吸虫病和丝虫病合作中心,上海200025

出　　处：《国际医学寄生虫病杂志》2009年第4期193-200,共8页International JOurnal of Medical Parasitic Diseases

摘　　要：三苯双脒是我国研制的一种广谱抗蠕虫新药。自2004年三苯双脒肠溶片被中国食品药品监督管理局审评通过后，2006—2007年又进行了Ⅳ期临床试验观察，在众多不同年龄的感染人群中，进一步证实成人和儿童分别用三苯双脒肠溶片400mg和200mg顿服治疗，对蛔虫和钩虫感染均有很好的疗效。三苯双脒对儿童蛲虫感染的治疗效果亦较好。近年来通过实验研究和临床观察证实三苯双脒对多种吸虫，包括华支睾吸虫、麝猫后睾吸虫、卡氏棘口吸虫，以及粪类圆线虫和带绦虫等均有效。该文综述了三苯双脒的研究新进展。Tribendimidine is a new broad-spectrum anthelmintic agent developed in China. Alter tribendimidine enteric-coated tablet was approved by the Chinese State Food and Drug Administration in 2004, a phase IV clinical trial was carried out during 2006-2007. Through the treatment of the larger sample of patients with intestinal helminthiasis and various ages, including children, the efficacy of tribendimidine enteric-coated tablet against Ascaris lumbricoides infection and hookworm infection was further confirmed, when the drug was administered orally to the adults and children patients at a single dose of 400 mg and 200 mg, respectively. Tribendimidine was also showed promising efficacy against Enterobius vermicularis infection in children. In recent years, the results from the laboratory study and clinical trial indicate that tribendimidine exhibits promising effect against several species of trematodes, including Clonorchis sinensis, Opistorchis viverrini, Echinostoma caproni, Strongyloides spp. and Taenia spp.. This paper summarizes the new progress on tribendimidine research.

关 键 词：三苯双脒肠溶片 化疗 蛔虫 钩虫 蛲虫 吸虫 绦虫 粪类圆线虫 

分 类 号：R532.1[医药卫生—内科学] R725.32[医药卫生—临床医学]